This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Investigators from several Charlotte, NC institutions and the University of Minnesota, Minneapolis conducted a prospective, randomized, blinded, non-inferiority trial comparing once-daily (1xd) with twice-daily (2xd) amoxicillin for the treatment of group A ß-hemolytic streptococcal (GABHS) pharyngitis. Patients with a positive rapid GABHS test were stratified by weight and then randomly assigned to receive either 1xd amoxicillin (750 mg if <40 kg, 1000mg if ≥40 mg) or 2xd amoxicillin (375 mg 2xd if <40 kg, 500 mg 2xd if ≥40 mg) for 10 days. Of 652 patients enrolled and randomized, …
Individual Login
Institutional Login
You may be able to gain access using your login credentials for your institution. Contact your librarian or administrator if you do not have a username and password.
Log in through your institution
Purchase access
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.